Research & Development

Lantern Pharma and NCI expand oncology partnership

Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.

Absci and Merck collaborate to develop new enzymes

Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.

Amgen, Generate Biomedicines partner to create protein therapeutics

Amgen has entered into a research collaboration agreement with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several modalities.

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.

Ascletis expands ritonavir oral tablets production amid Covid-19 surge

Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.

BSF Enterprise to acquire 3D Bio-Tissues

BSF Enterprise has signed a conditional agreement to acquire 3D Bio-Tissues (3DBT) in a deal worth $3.34m (£2.5m).

Ambys raises funding to expand liver cell therapy production capabilities

Ambys Medicines has secured $47m Series A financing extension for the continued expansion of its production capabilities of liver cell therapy.

Alpine Immune, Horizon enter autoimmune disease research collaboration

Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.

Bristol Myers Squibb signs deal with Immatics for solid tumour drug

Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter's TCR Bispecific candidate for solid tumours, IMA401.